TSX and TSXV rise as risk appetite improves. Netflix climbs ahead of earnings, Aurora Cannabis buys Safari Flower, oil and gold dip, and markets stay constructive.
TSX and TSXV rise as risk appetite improves. Netflix climbs ahead of earnings, Aurora Cannabis buys Safari Flower, oil and gold dip, and markets stay constructive.

The TSX is up 0.16%, while the TSX Venture Index is higher by 0.32%, as Canadian markets edge higher amid improving global risk sentiment. U.S. markets are mixed, with the Dow up 0.16%, while the Nasdaq is slightly lower, down 0.08%, as traders digest record highs in major indexes alongside lingering geopolitical uncertainty. In Europe, the FTSE 100 is outperforming, up 0.67%, reflecting stronger risk appetite overseas.

Commodities are leaning constructive. Oil is moving higher again, up 1.82%, as traders reassess Middle East risks despite easing war fears. Gold is rebounding, up 0.55%, supported by a softer dollar and renewed demand after recent volatility. Copper is modestly higher, natural gas is climbing, and Bitcoin is slightly lower in Canadian‑dollar terms as crypto consolidates after a strong run above US$75,000.

Market numbers

TSX: Up (+0.16%), 34,155.99

TSXV: Up (+0.32%), 1,043.31

DOW: Up (+0.16%), 48,577.5

NASDAQ: Down (‑0.08%), 26,206.7

FTSE 100: Up (+0.67%), 10,625.85

In the headlines

  • Allbirds rockets on last‑ditch AI pivot: Allbirds (NDAQ:BIRD) — the sustainable footwear brand once known for eco‑friendly shoes — surged an eye‑popping 583% after announcing a dramatic pivot away from footwear and toward AI‑focused operations just days before a planned wind‑down. Traders piled into the stock despite deep questions about the company’s long‑term viability.
  • Stellantis and Microsoft strike five‑year AI partnership: Stellantis (NYSE:STLA) — the global automaker behind Jeep, Ram, Fiat, and Chrysler — signed a five‑year partnership with Microsoft (TSX:MSFT), the software and cloud‑computing giant, to accelerate AI deployment across vehicle software, manufacturing, and connected‑services platforms.
  • Rogers expands satellite coverage into the U.S.: Rogers Communications (TSX:RCI.A) — one of Canada’s largest telecom providers — announced its satellite‑to‑phone coverage will expand into the United States through a partnership with T‑Mobile. The move extends Rogers’ reach in emergency connectivity and next‑generation wireless services.

Currencies

USD: Up (+0.18%), $0.7288

GBP: Up (+0.24%), $0.5381

EUR: Up (+0.41%), $0.61927

JPY: Up (+0.26%), ¥116.002

AUD: Up (+0.10%), $1.0163

Bitcoin (BTC/CAD): Down (‑0.58%), 102,208.4

(Conversion to C$1)

Commodities

Copper: Up (+0.15%), 604.54

Gold: Up (+0.55%), 4,817.01

WTI Crude: Up (+1.82%), 89.60

Natural Gas: Up (+1.66%), 2.637

To stay up-to-date on all of your market news head to Stockhouse.com.

Join the discussion: Find out what everybody’s saying about Allbird, Rogers, and Stellantis for April 16th, 2026, on Stockhouse’s stock forums and message boards.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.


More From The Market Online

Buzz on the Bullboards: Return trajectories vs emerging threats

Global markets entered this week uneasy, as geopolitics once again took centre stage. Traders brace for volatility tied to Middle East.

It was crazy & it worked: PS5 sales surge ahead of global price increase

PlayStation 5 sales jumped as buyers rushed ahead of Sony’s (NYSE:SONY) price increase. Prices rose sharply worldwide across all PS5 models.

New growth phase: Clean water technologies, nuclear‑grade resins, and a stronger balance sheet

Birchtech (TSX:BCHT) is emerging as a differentiated environmental technology company focused on specialty activated carbon.

Marvel Biosciences advancing autism drug for children

Marvel Biosciences announces two pediatric-friendly versions of its drug candidate, MB-204, which may help to treat autism and depression.